ACADIA Pharmaceuticals Inc.(NASDAQ:ACAD) Continues Innovation


Dallas, Texas 04/24/2014 (FINANCIALSTRENDS) –  ACADIA Pharmaceuticals Inc.(NASDAQ:ACAD) is one of the unique biopharmaceutical company’s which is focused on the development of a range of small molecule drugs for the treatment of such medical conditions as neurological as well as central nervous system disorders. There are all together four product types of candidates, which are under clinical development.

ACADIA Pharmaceuticals Inc.(NASDAQ:ACAD) has the company’s future riding on the drug pimavanserin. This drug is currently in the Phase 3 development as well as one of the most innovative treatment methods, deployed thus far for the treatment of Parkinson’s disease and psychosis.

ACADIA Pharmaceuticals Inc.(NASDAQ:ACAD) already holds rights and commercial permits to develop pimavanserin. In addition, it is noted that the product candidate for the Phase 2 development for such conditions as chronic pain.  The company also has a Phase I development product candidate for the condition called as glaucoma, which is typically used along with the treatment for Allergan Inc.

ACAD also has another drug for the treatment of schizophrenia, which is Phase 1 development stage. The product is also used with such drugs as Meiji Seika Pharma Co.

ACADIA Pharmaceuticals Inc.(NASDAQ:ACAD) has  a market capital of $1.98 billion. EPS of this company is -0.44. Outstanding shares for this company are in the region of 92.46 million. Beta is 3.16. The company has been trading on the stock market at prices which range between $19.90 and $21.12 per share. The shares of this company will also trade on a 52 week high of $32.00 and low of $11.26.

ACADIA Pharmaceuticals Inc.(NASDAQ:ACAD)  long line of products have contributed to the company’s growth in terms of product portfolio as well as the types of diseases it is able to support.

ACADIA Pharmaceuticals Inc.(NASDAQ:ACAD)drugs which are promising include- Alpha Adrenergic Agonists as well as Muscarinic Agonists drugs besides the AM-831.